Ali I Amjad1, Rahul A Parikh1, Leonard J Appleman1, Eun-Ryeong Hahm2, Kamayani Singh3, Shivendra V Singh2. 1. Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania ; University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania ; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
Sulforaphane (SFN) is a metabolic by product of cruciferous vegetables and is the biologically active phytochemical found in high concentrations in broccoli. It has been studied extensively for its anticancer efficacy and the underlying mechanisms using cell culture and preclinical models. The immediate precursor of SFN is glucoraphanin, a glucosinolate which requires metabolic conversion to SFN. SFN and other notable isothiocyanates, including phenethyl isothiocyanate and benzyl isothiocyanate found in various cruciferous vegetables, have also been implicated to have a chemopreventive role for breast, colon and prostate cancer. In-vitro and in-vivo anti-cancer activity of this class of compounds summarizing the past two decades of basic science research has previously been reviewed by us and others. The present review aims to focus specifically on SFN and its chemopreventive and antineoplastic activity against prostate cancer. Particular emphasis in this communication is placed on the current status of clinical research and prospects for future clinical trials with the overall objective to better understand the clinical utility of this promising chemopreventive nutraceutical in the context of mechanisms of prostate carcinogenesis.
Sulforaphane (n class="Gene">SFN) is a metabolic by product of cruciferous vegetables and is the biologically active phytochemical found in high concentrations in broccoli. It has been studied extensively for its anticancer efficacy and the underlying mechanisms using cell culture and preclinical models. The immediate precursor of SFN is glucoraphanin, a glucosinolate which requires metabolic conversion to SFN. SFN and other notable isothiocyanates, including phenethyl isothiocyanate and benzyl isothiocyanate found in various cruciferous vegetables, have also been implicated to have a chemopreventive role for breast, colon and prostate cancer. In-vitro and in-vivo anti-cancer activity of this class of compounds summarizing the past two decades of basic science research has previously been reviewed by us and others. The present review aims to focus specifically on SFN and its chemopreventive and antineoplastic activity against prostate cancer. Particular emphasis in this communication is placed on the current status of clinical research and prospects for future clinical trials with the overall objective to better understand the clinical utility of this promising chemopreventive nutraceutical in the context of mechanisms of prostate carcinogenesis.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: John D Clarke; Anna Hsu; David E Williams; Roderick H Dashwood; Jan F Stevens; Masayuki Yamamoto; Emily Ho Journal: Pharm Res Date: 2011-06-17 Impact factor: 4.200
Authors: Sunga Choi; Karen L Lew; Hui Xiao; Anna Herman-Antosiewicz; Dong Xiao; Charles K Brown; Shivendra V Singh Journal: Carcinogenesis Date: 2006-08-18 Impact factor: 4.944
Authors: Shivendra V Singh; Renaud Warin; Dong Xiao; Anna A Powolny; Silvia D Stan; Julie A Arlotti; Yan Zeng; Eun-Ryeong Hahm; Stanley W Marynowski; Ajay Bommareddy; Dhimant Desai; Shantu Amin; Robert A Parise; Jan H Beumer; William H Chambers Journal: Cancer Res Date: 2009-02-17 Impact factor: 12.701
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford Journal: N Engl J Med Date: 2013-08-15 Impact factor: 91.245
Authors: W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640
Authors: Zhenzhen Zhang; Mark Garzotto; Edward W Davis; Motomi Mori; Wesley A Stoller; Paige E Farris; Carmen P Wong; Laura M Beaver; George V Thomas; David E Williams; Roderick H Dashwood; David A Hendrix; Emily Ho; Jackilen Shannon Journal: Nutr Cancer Date: 2019-06-01 Impact factor: 2.900
Authors: Gavin S Johnson; Jia Li; Laura M Beaver; W Mohaiza Dashwood; Deqiang Sun; Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood Journal: Mol Nutr Food Res Date: 2017-01-03 Impact factor: 5.914